Atypical fracture of the femur in a patient with postmenopausal osteoporosis after four injections of zoledronic acid

Abstract

Bisphosphonates are one of the most effective medications widely used in the treatment of osteoporosis. In the last 15 years, descriptions, and observations of unusual low-energy femoral fractures with atypical localization for osteoporosis after prolonged use of these drugs have been published.

A 78-year-old patient applied to the osteoporosis center. She received parenteral bisphosphonate therapy for severe osteoporosis for 4 years. In 2017, a spontaneous fracture of the middle third of the femoral shaft was registered (the fracture occurred while walking). Regarding the fracture, metal osteosynthesis with a plate was performed. Subsequently, there was a delayed consolidation of the fracture with the formation of a false joint and the need for repeated surgical intervention. Examination of the patient revealed vitamin D deficiency, and significant negative trend in densitometry.

A feature of this case is poor fracture consolidation and long-term uncompensated vitamin D deficiency. Physicians should be aware of this rare but serious complication of bisphosphonate therapy, as it requires discontinuation of antiresorptive drugs and the appointment of bone anabolic therapy for osteoporosis, which, in addition to treating the underlying disease, also promotes consolidation fracture.

Keywords

osteoporosis / atypical fracture of the femur / bisphosphonates

References

[1] Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2–19. DOI: 10.1016/j.bone.2011.04.022

[2] Russell R.G. Bisphosphonates: the first 40 years // Bone. 2011. Vol. 49, No. 1. P. 2–19. DOI: 10.1016/j.bone.2011.04.022

[3] Girgis CM, Seibel MJ. Bisphosphonate use and femoral fractures in older women. JAMA. 2011;305(20):2068; author reply 2069. DOI: 10.1001/jama.2011.673

[4] Girgis C.M., Seibel M.J. Bisphosphonate use and femoral fractures in older women // JAMA. 2011. Vol. 305, No. 20. P. 2068; author reply 2069. DOI: 10.1001/jama.2011.673

[5] Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305(8):783–789. DOI: 10.1001/jama.2011.190

[6] Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N. et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women // JAMA. 2011. Vol. 305, No. 8. P. 783–789. DOI: 10.1001/jama.2011.190

[7] Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–1771. DOI: 10.1056/NEJMoa1001086

[8] Black D.M., Kelly M.P., Genant H.K. et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur // N. Engl. J. Med. 2010. Vol. 362, No. 19. P. 1761–1771. DOI: 10.1056/NEJMoa1001086

[9] Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346–350. DOI: 10.1097/BOT.0b013e318172841c

[10] Neviaser A.S., Lane J.M., Lenart B.A. et al. Low-energy femoral shaft fractures associated with alendronate use // J. Orthop. Trauma. 2008. Vol. 22, No. 5. P. 346–350. DOI: 10.1097/BOT.0b013e318172841c

[11] Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–1301. DOI: 10.1210/jc.2004-0952

[12] Odvina C.V., Zerwekh J.E., Rao D.S. et al. Severely suppressed bone turnover: a potential complication of alendronate therapy // J. Clin. Endocrinol. Metab. 2005. Vol. 90, No. 3. P. 1294–1301. DOI: 10.1210/jc.2004-0952

[13] Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009;80(4):413–415. DOI: 10.3109/17453670903139914

[14] Schilcher J., Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate // Acta. Orthop. 2009. Vol. 80, No. 4. P. 413–415. DOI: 10.3109/17453670903139914

[15] Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res.2014;29(1):1–23. DOI: 10.1002/jbmr.1998

[16] Shane E., Burr D., Abrahamsen B. et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research // J. Bone Miner. Res. 2014. Vol. 29, No. 1. P. 1–23. DOI: 10.1002/jbmr.1998

[17] Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24(6):1095–1102. DOI: 10.1359/jbmr.081247

[18] Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study // J. Bone Miner. Res. 2009. Vol. 24, No. 6. P. 1095–1102. DOI: 10.1359/jbmr.081247

[19] Nieves JW, Bilezikian JP, Lane JM, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int. 2010;21(3):399–408. DOI: 10.1007/s00198-009-0962-6

[20] Nieves J.W., Bilezikian J.P., Lane J.M. et al. Fragility fractures of the hip and femur: incidence and patient characteristics // Osteoporos. Int. 2010. Vol. 21, No. 3. P. 399–408. DOI: 10.1007/s00198-009-0962-6

[21] Maman E, Briot K, Roux C. Atypical femoral fracture in a 51-year-old woman: Revealing a hypophosphatasia. Joint Bone Spine. 2016;83(3):346–348. DOI: 10.1016/j.jbspin.2015.10.009

[22] Maman E., Briot K., Roux C. Atypical femoral fracture in a 51-year-old woman: Revealing a hypophosphatasia // Joint Bone Spine. 2016. Vol. 83, No. 3. P. 346–348. DOI: 10.1016/j.jbspin.2015.10.009

[23] Lim SJ, Yeo I, Yoon PW, et al. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study. Osteoporos Int. 2018;29(11):2427–2435. DOI: 10.1007/s00198-018-4640-4

[24] Lim S.J., Yeo I., Yoon P.W. et al. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study // Osteoporos. Int. 2018. Vol. 29, No. 11. P. 2427–2435. DOI: 10.1007/s00198-018-4640-4

[25] Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16–35. DOI: 10.1002/jbmr.2708

[26] Adler R.A., El-Hajj Fuleihan G., Bauer D.C. et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research // J. Bone Miner. Res. 2016. Vol. 31, No. 1. P. 16–35. DOI: 10.1002/jbmr.2708

[27] Zotkina KE, Lesnyak OM, Kochish AYu, Sushkov IV. A case of atypical femur fracture during long-term treatment with bisphosphonates in patient with postmenopausal osteoporosis. Osteoporosis and Bone Diseases. 2019;22(1):18–23. (In Russ.). DOI: 10.14341/osteo10286

[28] Зоткина К.Е., Лесняк О.М., Кочиш А.Ю., Сушков И.В. Атипичный перелом бедренной кости на фоне лечения бисфосфонатами пациентки с постменопаузным остеопорозом // Остеопороз и остеопатии. 2019. Т. 22, № 1. С. 18–23. DOI: 10.14341/osteo10286

[29] Buklemishev YuV, Rodionova SS, Krivorotko MS. Difficulties in treatment of atypical femoral fractures (clinical case). Osteoporosis and Bone Diseases. 2020;23(1):62. (In Russ.)

[30] Буклемишев Ю.В., Родионова С.С., Криворотько М.С. Трудности в лечении атипичных переломов бедренной кости (описание клинического случая) // Остеопороз и остеопатии. 2020. Т. 23, № 1. С. 62.

RIGHTS & PERMISSIONS

Gladkova E.N., Lesnyak O.M.